SCHEMBL4674447

SCHEMBL4674447

O=C(Cc1ccc(Sc2ccc(Cl)cc2)o1)C(=O)c1nc[nH]n1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 2/20 0.37
SMN1; SMN2 Q16637 2/20 0.37
KDM4E B2RXH2 3/20 0.35
CYP1A2 P05177 3/20 0.35
CYP2C9 P11712 3/20 0.35
CYP3A4 P08684 2/20 0.35
CYP2C19 P33261 2/20 0.35
CYP2D6 P10635 1/20 0.35
HAO1 Q9UJM8 2/20 0.34
PTPN11 Q06124 1/20 0.34
MAPT P10636 4/20 0.33
MEN1 O00255 3/20 0.33
KMT2A Q03164 3/20 0.33
GAA P10253 2/20 0.33
TP53 P04637 1/20 0.33
NPSR1 Q6W5P4 2/20 0.32
XBP1 P17861 1/20 0.32
MAPK1 P28482 1/20 0.32
RECQL P46063 1/20 0.32
HTT P42858 2/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4673234 0.89 ALDH1A1 (0.32) POLBMAPTNPSR1ALDH1A1PKM
SCHEMBL4673974 0.89 MAPT (0.31) MAPT
SCHEMBL4675831 0.89 ALDH1A1 (0.36) SMN1; SMN2KDM4ECYP1A2CYP2C19MAPT
SCHEMBL4672393 0.89 CYP2C9 (0.32) CYP2C9CYP2C19HPGD
SCHEMBL4673815 0.87 PTPN11 (0.38) POLBKDM4EPTPN11MAPTMEN1
SCHEMBL4672388 0.87 ALDH1A1 (0.36) POLBSMN1; SMN2KDM4EHAO1MAPT
SCHEMBL4673379 0.87 HAO1 (0.34) HAO1ALDH1A1
SCHEMBL4670835 0.87 HPGD (0.38) LMNAALDH1A1HPGD
SCHEMBL4678602 0.82 SMN1; SMN2 (0.38) POLBSMN1; SMN2KDM4EMAPTKMT2A
SCHEMBL4676645 0.82 PTPN11 (0.36) HAO1PTPN11MAPTMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1142872-B1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO (JP) 2008-10-15 EP disclosed
US-7098201-B2 Heteroaromatic derivatives having an inhibitory activity against HIV integrase SHIONOGI & CO., LTD. (JP) 2006-08-29 US disclosed
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase FUJISHITA TOSHIO (JP) 2004-01-01 US disclosed
US-6645956-B1 1-(5-(4-fluorobenzyl)furan-2-yl)-3-hydroxy-3-(1H-1,2,4-triazol-3 -yl)-propenone; viricides; AIDS treatment SHIONOGI & CO., LTD. (JP) 2003-11-11 US disclosed
US-6620841-B1 Furan or benzofuran derivatives substituted with triazole; acquired immunodeficiency syndrome (AIDS) SHIONOGI & CO., LTD. (JP) 2003-09-16 US disclosed
EP-1142872-A1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO., LTD. (JP) 2001-10-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase RCOR1, BCOR, CYP8B1 POLB 58/4885SMN1; SMN2 4107/4885KDM4E 947/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.